Navigation Links
Thomson Reuters Partners with CHDI Foundation to Develop Systems Biology Tools for Huntington's Disease
Date:7/26/2012

PHILADELPHIA, July 26, 2012 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today announced a partnership with CHDI Foundation, Inc. to develop systems biology tools for Huntington's disease (HD) research. HD is a devastating neurodegenerative disorder that affects muscle coordination and leads to gradual cognitive decline and dementia; there are currently no effective treatments available. The collaboration will include reconstruction and analysis of causal networks underlying HD mechanisms and building a comprehensive collection of HD pathology pathway maps to assist researchers worldwide.  

"Building a clearer, more detailed understanding of Huntington's disease that leads to the development of therapies is CHDI's top priority," said Keith Elliston, vice president of systems biology at CHDI. "We are very pleased to be collaborating with Thomson Reuters to provide the whole HD research community with valuable tools that will further our knowledge of the disease and bring us closer to effective therapeutic options for patients."

One of the central goals of the MetaMiner Partnership will be to identify disease mechanisms through network analysis of gene expression data in HD patients with different numbers of CAG repeats in the huntingtin (HTT) gene. The number of CAG repeats is a predictor of the age of disease onset.

A second objective of the collaboration will be to build pathology pathway maps for disease mechanisms, continuing the work of MetaMiner™ for HD, a program that focuses on HD pathway reconstruction. This project, a collaborative effort between Thomson Reuters, as well as selected pharmaceutical companies and universities, has generated 15 specific HD pathway maps. Thomson Reuters builds causal networks and pathway maps using a proprietary manual curation technology and full text peer-review literature as a source of protein interactions.

"The pathway maps and unique content Thomson Reuters is developing for this collaborative effort with CHDI are especially valuable in shedding light on Huntington's disease and its mechanisms," said Jon Brett-Harris, executive vice president, Life Sciences, Thomson Reuters. "The maps will provide HD researchers with a resource to reveal the mechanisms behind the disease and further extend the drug discovery process. We are honored to have the opportunity to work with CHDI as a research partner on this critical program, and to be able to contribute our state-of-the-art content with high value professional services and research capabilities."

Once complete, the images of the new HD pathway maps will be available on CHDI's website and through MetaCore. Users of MetaCore, an integrated software suite for functional data analysis, will be able to access the HD pathway maps for greater insight via MetaCore's analysis tools.

For more information about pathway analysis tools at Thomson Reuters, please visit http://thomsonreuters.com/products_services/science/science_products/a-z/metacore/.

ABOUT CHDI
CHDI Foundation, Inc. is a privately-funded, not-for-profit, biomedical research organization exclusively dedicated to rapidly discovering and developing therapies that slow the progression of Huntington's disease. As a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. Our scientists work closely with a network of more than 600 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing strategic scientific direction to ensure that our common goals remain in focus. More information about CHDI can be found at www.chdifoundation.org

ABOUT THOMSON REUTERS
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
2. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
3. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
4. The PROOF Centre of Excellence Partners with OriGene Technologies on Heart & Kidney Transplant Biomarker Program
5. NineSigma Partners with Scientists Without Borders to Find New Sustainable Packaging for Micronutrient Powders that Combat Malnutrition
6. HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
7. Elsevier and The Geological Society of London Take Home the 2012 Getenergy Award for Education / Industry Partnership
8. Clean Energy Alliance and the Manufacturing Extension Partnership Announce New Collaboration
9. DOE-CEA Partnership Awards Mentoring Services to Finalists in National Clean Energy Business Plan Competition
10. Economic Alliance of Greater Baltimore Inks Business Partnership with BioHealth Innovation to Bring Health and Life Sciences Research to Market
11. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)... , ... February 15, 2017 , ... ... as President and Chief Commercial Officer with GenePeeks. Matt is a veteran ... GenePeeks is a computational genomics company focused on identifying inherited disease risk in ...
(Date:2/15/2017)... Februar 2017  Trianni, Inc. („TRIANNI") gab heute ... eine Lizenzvereinbarung über die Verwendung der The Trianni ... für die Entdeckung monoklonaler Antikörper. Die ... Gensegmentdesign aus, das Janssen den Zugang ... und das für die schelle Isolierung vollständig menschlicher ...
(Date:2/15/2017)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today ... quarter and full year ended December 31, 2016. ... Vanda as we continued to demonstrate strong growth ... for Fanapt," said Mihael H. Polymeropoulos, M.D., Vanda,s ... with important 2017 milestones underscores Vanda,s commitment to ...
(Date:2/15/2017)... -- Windtree Therapeutics, Inc. (Nasdaq: WINT ), ... therapies for respiratory diseases, will host a conference call ... EST on Thursday, February 16, 2017 to provide updates ... announced closing of a $10.5 million private offering and ... in the live call and take part in the ...
Breaking Biology Technology:
(Date:2/6/2017)... -- According to Acuity Market Intelligence, ongoing concerns ... continue to embrace biometric and digital identification based ... Control (ABC) eGates and 1436 Automated Passport Control ... ports of entry across the globe. Deployments increased ... CAGR of 37%. APC Kiosks reached 75% growth ...
(Date:2/2/2017)...  Central to its deep commitment to honor ... Japan Prize Foundation today announced the laureates of ... envelope in their respective fields of Life Sciences ... being recognized with the 2017 Japan Prize for ... to the advancement of science and technology, but ...
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
Breaking Biology News(10 mins):